Wells Fargo & Company MN Buys 913 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Wells Fargo & Company MN raised its stake in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 29.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,016 shares of the company’s stock after purchasing an additional 913 shares during the period. Wells Fargo & Company MN’s holdings in Gyre Therapeutics were worth $49,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Barclays PLC grew its holdings in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares during the period. Bank of New York Mellon Corp grew its holdings in Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after acquiring an additional 1,389 shares during the period. SBI Securities Co. Ltd. acquired a new stake in Gyre Therapeutics during the 4th quarter worth about $1,225,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Gyre Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock worth $1,386,000 after acquiring an additional 918 shares during the period. 23.99% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Noble Financial assumed coverage on Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating for the company.

Gyre Therapeutics Price Performance

Shares of GYRE opened at $11.50 on Wednesday. The stock has a 50-day moving average of $9.06 and a 200-day moving average of $10.93. The company has a market cap of $1.08 billion, a PE ratio of 575.00 and a beta of 1.90. Gyre Therapeutics, Inc. has a one year low of $6.11 and a one year high of $19.00.

Gyre Therapeutics (NASDAQ:GYRE) last issued its earnings results on Friday, May 9th. The company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The company had revenue of $22.06 million during the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.

Gyre Therapeutics Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.